Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)

Andrew  Blauvelt; Anderas Wollenberg; Andrew Pink; Ketty  Peris; April Armstrong; Lynda Spelman; Hidehisa Saeki; Charles Lynde; Pedro Herranz; Sebastien Barbarot; Eric Simpson

doi:10.25251/skin.5.supp.57

Andrew Blauvelt

Oregon Medical Research Center, Portland, OR, USA

Anderas Wollenberg

Department of Dermatology and Allergology, Ludwig-Maximilian University of Munich, Munich, Germany

Andrew Pink

St. John’s Institute of Dermatology, Guy’s and St. Thomas’ Hospitals, London, UK

Ketty Peris

Dermatology, Catholic University and Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy

April Armstrong

Keck School of Medicine at University of Southern California, Los Angeles, CA, USA

Lynda Spelman

Veracity Clinical Research, Brisbane, Queensland, Australia, and Probity Medical Research, Woolloongabba, Queensland, Australia

Hidehisa Saeki

Department of Dermatology, Nippon Medical School, Tokyo, Japan

Charles Lynde

Lynde Dermatology, Probity Medical Research, Markham, Ontario, Canada

Pedro Herranz

Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain

Sebastien Barbarot

Centre Hospitalier Universitaire de Nantes, Nantes, France

Eric Simpson

Department of Dermatology, Oregon Health & Science University, Portland, OR, USA

Keywords

tralokinumab, atopic dermatitis, ECZTRA trial, efficacy

Abstract

N/A

References

1. Weidinger S, Novak N. Lancet. 2016;387:1109-22.

2. Silverberg JI, et al. Ann Allergy Asthma Immunol. 2018;121:340-7.

3. Dalgard FJ, et al. J Invest Dermatol. 2015;135:984-91.

4. Szegedi K, et al. J Eur Acad Dermatol Venereol. 2015;29:2136-44.

5. Popovic B, et al. J Mol Biol. 2017;429:208-19.

6. Furue K, et al. Immunology. 2019;158:281-6.

7. Tsoi LC, et al. J Invest Dermatol. 2019;139:1480-9.

8. Bieber T. Allergy. 2020;75:54-62.

9. Wollenberg A, et al. Br J Dermatol. 2021;184:437-49.

Poster PDF

Published

Nov 5, 2021

DOI https://doi.org/10.25251/skin.5.supp.57

How to Cite

Blauvelt, A. ., Wollenberg, A., Pink, A., Peris, K. ., Armstrong , A., Spelman, L., Saeki, H., Lynde, C., Herranz, P., Barbarot, S., & Simpson, E. (2021). Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2). SKIN The Journal of Cutaneous Medicine, 5(6), s57. https://doi.org/10.25251/skin.5.supp.57

Issue

Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)

Section

Atopic Dermatitis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Richard Warren , April Armstrong , Melinda Gooderham, Bruce Strober , Diamant Thaci, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil Korman, Min Zheng, Elizabeth Colston, John Throup , Sundeep Kundu, Renata Kisa, Subhashis Banerjee, Andrew Blauvelt, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Amy Paller, Andrew Blauvelt, Weily Soong, Shinichi Imafuku, Chih-ho Hong, Marie Schuttelaar, Petra Amoudruz, Azra Kurbasic, Lise Soldbro, Katja Lophaven, Michael Cork, Anthony Bewley, Eric Simpson, Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Mark Lebwohl, Linda Stein Gold, Bruce Strober, April Armstrong, H Chih-Ho Hong, Leon Kircik, Jennifer Soung, Jeff Fromowitz, Scott Guenthner, Stephen Piscitelli, David Rubenstein, Philip Brown, Anna Tallman, Robert Bissonnette, Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Todd Schlesinger, Leon Kircik, James Del Rosso, Darrell Rigel, Mark Lebwohl, Brian Berman, April Armstrong, Neal Bhatia, Vishal A. Patel, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Clinician- and Patient-Reported Outcomes with Tirbanibulin 1% Treatment for Actinic Keratosis in Routine Clinical Practice Across the U.S. (PROAK Study) , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 3 (2023): May Issue and Posters from WCH23 & WCM23
Andrew Blauvelt, Steven Kempers, Todd Schlesinger, Edward Lain, Hui Wang, David Cutler, Mark Lebwohl, Jane Fang, Rudolf Kwan, Tirbanibulin Ointment 1% for Actinic Keratosis (AK): Pooled Data from Two Phase 3 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Danny Zakria, April Armstrong, Brian Berman, James Del Rosso, Mark Lebwohl, Todd Schlesinger, Darrell Rigel, The Importance of Medication Adherence in the Treatment of Actinic Keratosis: An Expert Consensus Panel , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 3 (2023): May Issue and Posters from WCH23 & WCM23
Andrew Blauvelt, Steven Kempers, Seth Forman, Edward Lain, Suzanne Bruce, Tirbanibulin Ointment 1%, a Novel Inhibitor of Tubulin Polymerization and Src Kinase Signaling , for the Treatment of Actinic Keratosis (AK): Results from Two Pivotal Phase III Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Bruce Strober, Michael Bukhalo, April Armstrong, David Pariser, Leon Kircik, Sepideh Parhami, Paul Montgomery, Tobin Dickerson, Interim Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
April Armstrong , Bruce Strober , Kenneth Gordon , Joe Zhuo, Brandon Becker, Renata Kisa, John Throup, Jonghyeon Kim, Kim Papp, Deucravacitinib Improves Psoriasis Symptoms and Signs Diary Domain Scores in Patients With Moderate to Severe Plaque Psoriasis: Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Bruce Strober , Linda Stein Gold, Robert Bissonnette, April Armstrong , Andrew Blauvelt, Philip Brown, Leon Kircik, Anna Tallman, Mark Lebwohl, Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)

1 2 3 4 5 6 7 8 9 10 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Most read articles by the same author(s)